# Clene (NASDAQ: CLNN) CEO and CFO Present at 72nd Emerging Growth Conference

* Clene’s CEO Rob Etherington and CFO Morgan Brown presented highlights and updates on the company’s pipeline – as well as answering questions from the audience
* Clene has conducted several clinical trials to test the efficacy of CNM-Au8(R), focusing on the diseases amyotrophic lateral sclerosis and multiple sclerosis
* CNM-Au8 has shown a favorable safety profile, with over 650 collective years of subject exposure without any major safety signals attributed to CNM-Au8
* Negotiations are underway to extend the cash runway into 2025, including potential licensing deals and the exercise of warrants that could bring in up to $130 million in additional capital for the company

 Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently participated in the 72nd Emerging Growth Conference. EmergingGrowth.com is a leading independent small cap media portal that identifies companies with strong management teams, innovative products, focused strategy and overall potential for long-term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts. Clene’s CEO Rob Etherington and CFO Morgan Brown presented highlights and updates on the company’s pipeline – as well as answering questions from the audience.

 The Emerging Growth Conference, moderated by award-winning journalist Ana Berry, is considered an effective way for public companies to engage with the investment community. Companies present new products, services, and make other announcements significant to their industry. During the event…

 Read More>>

 NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

 Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

 The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

 Corporate Communications

 IBN (InvestorBrandNetwork)Los Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com 

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ult-prem/clene-nasdaq-clnn-ceo-and-cfo-present-at-72nd-emerging-growth-conference/)
                    

[Newsramp.com TLDR](None) 

https://www.reddit.com/r/HealthCareNewsInfo/comments/1f2qeoy/clene_nasdaq_clnn_ceo_and_cfo_present_corporate/